Researchers from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine will present a selection of the latest advances in hematology research at this year's American Society of Hematology (ASH) Annual Meeting, December 5-8, at the Orange County Convention Center in Orlando, Fla.
Highlights of research presented by Sylvester researchers include:
Oral Presentations:
Monday, December 7
The small molecule Img-98, a potent and selective inhibitor of the lysine demethylase Lsd-1, effectively augments the pro-differentiation effects of all-trans-retinoic acid (ATRA) in a pre-clinical model of acute myeloid leukemia (AML) Ronan Swords; presentation #460; 7:45 a.m.; W109, Level 1
Grb2 directly interacts with HGAL and ameliorates its effects on B-cell receptor signaling Izidore Lossos; presentation #702; 4 p.m.; W311EFGH, Level 3
Poster Presentations:
Saturday, December 5
Pharmacokinetics of red cell microparticles (RMP) in rabbits and rats: effects of administration, regimen and label of assay Wenche Jy; poster #1146; 5:30-7:30 p.m.; Hall A, Level 2
Inhibition of the PI3K/AKT/mTOR pathway leads to down regulation of c-Myc and overcomes resistance to all-trans-retinoic acid (ATRA) in acute myeloid leukemia Ronan Swords; poster #1363; 5:30-7:30 p.m.; Hall A, Level 2
The combination of belinostat with zidovudine for treatment of HTLV-I-related adult T-cell leukemia-lymphoma Juan Carlos Ramos; poster #1562; 5:30-7:30 p.m.; Hall A, Level 2
Sunday, December 6
A patient-specific ex vivo screening platform for personalized acute myeloid leukemia (AML) therapy Ronan Swords; poster #1352; 5:30-7:30 p.m.; Hall A, Level 2
The BET bromodomain inhibitors EP11313 and EP11336 have potent anti-leukemic activity in acute myeloid leukemia (AML) and augment the effects of all-trans-retinoic acid (ATRA) in vitro Ronan Swords; poster #2552; 6-8 p.m.; Hall A, Level 2
Monday, December 7
Elevated red cell microparticles (RMP) in hematologic and thrombotic disorders Wenche Jy; poster #3553; 6-8 p.m.; Hall A, Level 2
In acute myeloid leukemia (AML), targeting the histone methyltransferase EZH2 promotes differentiation, impairs clonogenic survival and augments the anti-leukemic effects of the retinoid, all-trans-retinoic acid (ATRA) Ronan Swords; poster #3786; 5-8 p.m.; Hall A, Level 2
FBXO10 targets HGAL for degradation Izidore Lossos; poster #3904; 6-8 p.m.; Hall A, Level 2
Join the conversation about this year's ASH Annual Meeting by using the hashtag #ASH2015 on Facebook, Twitter and Instagram.